Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed…
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over…
Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of…
The FDA says it is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs. “FDA…
The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market volatility, tariffs and a slowly dethawing IPO market continued to cast…
Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset. “Nurix regularly reviews its operations to ensure we are effectively…
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. The Johnson & Johnson-partnered…
Editor’s note: The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of Chutes & Ladders will publish Dec. 5. Welcome to this…
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The company is ending…
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control…